Medtronic, Aetna Partner On Insulin Pump Cost-Savings Program
The device maker and insurance provider are collaborating to provide discounted Medtronic insulin pumps to Aetna members who have uncontrolled type 2 diabetes.
You may also be interested in...
The first fully functional artificial pancreas for patients with diabetes could be ready for regulatory submission in the next few years. Medtronic has achieved notable success in this area to date, but positive clinical studies have put J&J in a good position as well, and the medical community is watching closely as the major developments in this groundbreaking endeavor continue to move forward.
Loss of exclusivity and other competitive pressures will continue to offset J&J’s pharmaceutical growth as its former blockbusters accumulate in ex-growth "other" categories. Can the pipeline take up the slack?
Roche remains the European sector’s biggest company despite a wobble in 2022, but Novo Nordisk’s spectacular growth has seen it overtake AstraZeneca and Novartis in market cap terms.